The Efficacy of the IUrisure for Detection of Recurrent Urothelial Carcinoma

NCT06564363 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 148

Last updated 2024-08-21

No results posted yet for this study

Summary

The clinical trial was designed to determine the efficacy (sensitivity and specificity) of the IUrisure test compared to the gold standard cystoscopy and pathology in patients under monitoring for recurrence of urothelial carcinoma.

Conditions

Interventions

DIAGNOSTIC_TEST

IUrisure test

Postoperative patients are followed up every three months on average, and IUrisure test was performed at each follow-up visit.

Sponsors & Collaborators

  • Wuhan Ammunition Life-tech Co., Ltd

    lead INDUSTRY

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-06-01
Primary Completion
2025-09-30
Completion
2025-12-31

Countries

  • China

Study Locations

More Related Trials

Entities

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06564363 on ClinicalTrials.gov